Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.
复制标题
DOI：
10.2174/156800912803987977
复制
发表时间：
2012-11
影响因子：
3
通讯作者：
Y. Hoshida;B. Fuchs;K. Tanabe
中科院分区：
文献类型：
--
作者：
Y. Hoshida;B. Fuchs;K. Tanabe
病毒性肝炎等慢性纤维化肝病最终发展为肝硬化，导致肝细胞癌的发生。鉴于晚期HCC的治疗效果有限，预防HCC发展可能是改善患者预后的有效策略。然而，目前仍没有既定的治疗方法来实现这一目标。研究已经阐明了参与HCC发展的多种分子机制和信号通路。基因工程或化学治疗的肝硬化和HCC实验模型已经开发出来，并在研究HCC预防的分子治疗靶点和诊断生物标志物方面显示出其潜在价值。在这篇综述中，我们概述了潜在的预防目标和目前可用的实验模型，并讨论了将研究结果转化为临床实践的策略。
Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.